Reply to Evans and Woodward

Christian P. Kratz, M.D.[1]; Dmitrii Smirnov, M.S.[2,3]; Robert Autry, Ph.D.[4-6]; Natalie Jäger, Ph.D.[4-6]; Sebastian M. Waszak, Ph.D.[7,8]; Anika Großhennig, Ph.D.[9]; Riccardo Berutti, Ph.D.[2,3]; Mareike Wendorff, Ph.D.[10]; Pierre Hainaut, Ph.D.[11]; Stefan M. Pfister[4-6,12], M.D.; Holger Prokisch, Ph.D.[2,3]; Tim Ripperger, M.D., Ph.D.[13]; David Malkin, M.D.[14-17]

[1]Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

[2]Institute of Human Genetics, School of Medicine, Technische Universität München, München, Germany.

[3]Institute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany.

[4]Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.

[5]Division of Paediatric Neurooncology, German Cancer Research Center (DKFZ), Germany.

[6]German Cancer Consortium (DKTK), Heidelberg, Germany.

[7]Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.

[8]Department of Neurology, University of California, San Francisco, San Francisco, CA, United States.

[9]Institute of Biostatistics, Hannover Medical School, Hannover, Germany;

[10]Institute of Clinical Molecular Biology, Christian-Albrechts-University, 24105 Kiel, Germany.

[11]Institute for Advanced Biosciences, Inserm 1209 CNRS 5309 UGA, Grenoble, France.

[12]Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

[13]Department of Human Genetics, Hannover Medical School, Hannover, Germany.

[14]Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.

[15]Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

[16]Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.

[17]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Address Correspondence to: C.P. Kratz, MD, Pediatric Hematology and Oncology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany; e-mail: kratz.christian@mh-hannover.de, phone: +49 (0)511 532 6711

We thank Drs. Evans and Woodward for their correspondence (1), in which the following points related to our publication entitled “Heterozygous *BRCA1*/2 and mismatch repair gene pathogenic variants in children and adolescents with cancer” are raised:

Point 1: The frequency of pathogenic/likely pathogenic variants (PVs) in the German control is lower than the frequency observed in published series. We agree with this point and for this reason, we included an analysis of cancer-free gnomAD controls. The enrichment of PVs in *BRCA1/2* and mismatch repair (MMR) genes was reproduced – with borderline statistical significance for PVs in *BRCA1/2* combined – when we used gnomAD controls only. Similar results were reproduced in a supplementary analysis including 17 studies. In addition, analysis of a validation cohort confirmed an enrichment of PVs in *BRCA2* and *MSH2* – but not in *PMS2* – compared to gnomAD controls. Notably, there are other independent recent publications (2-5) including one study focusing on the somatic mutation landscape (2) supporting the association between Lynch syndrome and childhood cancer. Other recent papers have demonstrated an enrichment of PVs in *BRCA2* in children with cancer (6, 7). Together, these studies suggest that these syndromes have a low penetrant pediatric spectrum.

Point 2: Variants may have been missed (e.g. in PMS2) and copy number variants were not included. Different sequencing pipelines and differences in pathogenicity assessment can confound burden testing. Therefore, we restricted our meta-analysis that included studies employing different pipelines to ClinVar PVs. This led to the intentional exclusion of copy number variants not included in ClinVar, however, this factor affects both cases and controls. We agree that difficulties in detecting variants are likely to influence the reported PV frequencies of our study, however, this factor affects both cases and controls. Future studies should analyze cases and controls employing the exact same pipeline and pathogenicity assessment strategy, and should include copy number variants.

Point 3: Bi-allelic gene variants were not ruled out. This point cannot be addressed due to the retrospective nature of our study. Based on our results we now recommend functional assays (e.g. chromosomal breakage test) to rule out Fanconi anemia in children with cancer

who are found to have a heterozygous PV in *BRCA1, BRCA2*, or *PALB2*. It is possible that a second germline PV on the other allele is missed when sequencing is employed alone. We recommend a similar procedure in children with cancer who are found to harbor a heterozygous germline PV in a MMR gene to rule out constitutional MMR deficiency due to bi-allelic PVs in one of the MMR genes.

Despite these limitations, our data provide evidence supporting the hypothesis that heterozygous PVs in *BRCA* and MMR genes (with the strongest signal observed for *MSH2*) are associated with pediatric cancer with a low penetrance not necessitating changes to current predictive testing recommendations. Prospective studies are needed to independently confirm these findings and to define the pediatric cancer spectra, tumor risks, and somatic mutation landscapes associated with PVs in these genes.

Funding

CPK and SMP have been supported by the Deutsche Kinderkrebsstiftung (DKS2019.13) and BMBF ADDRess (01GM1909A and 01GM1909E). RA is supported by the Everest Centre for Low-Grade Paediatric Brain Tumours (the Brain Tumour Charity, UK; GN-000382). SMW is supported by the Research Council of Norway (187615), the South-Eastern Norway Regional Health Authority, and the University of Oslo. TR has been supported by BMBF MyPred (01GM1911B). DM is supported by grants from the Canadian Institutes for Health Research (FDN-143234) and the Terry Fox Research Institute (TFRI #1081). DS and HP have been supported by BMBF (01GM1906B).

Notes

The role of the funder: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author contributions: Conceptualization: CPK; Writing – review & editing: all authors.

Author disclosures: None exist

Data Availability

No new data were generated or analyzed for this response.

References

1. Evans DGE, Woodward E. Ref:Heterozygous BRCA1/BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer. J Natl Cancer Inst. 2022. In press.

2. Suwala AK, Stichel D, Schrimpf D*, et al.* Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol 2021;141(1):85-100.

3. Scollon S, Eldomery MK, Reuther J*, et al.* Clinical and molecular features of pediatric cancer patients with Lynch syndrome. Pediatr Blood Cancer 2022;69(11):e29859.

4. MacArthur TA, Ongie LJ, Lanpher BC*, et al.* Pediatric manifestations of Lynch Syndrome: A single center experience. J Pediatr Surg Case Rep 2022;86.

5. Self C, Suttman A, Wolfe Schneider K*, et al.* Lynch syndrome: further defining the pediatric spectrum. Cancer Genet 2021;258-259:37-40.

6. Li H, Sisoudiya SD, Martin-Giacalone BA*, et al.* Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children's Oncology Group. J Natl Cancer Inst 2020; 10.1093/jnci/djaa204.

7. Gillani R, Camp SY, Han S*, et al.* Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet 2022;109(6):1026-1037.